Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More
Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.
Healthcare product and device company Abbott Laboratories (NYSE:ABT) announced better-than-expected revenue in Q1 CY2026, with sales up 7.8% year on year to ...
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66
As the sun sets on the era of easy profits from elevated interest rates, the titans of Wall Street are preparing to unveil a new chapter in their growth stories. For the first time in three years, the narrative surrounding the upcoming Q1 2026 earnings for Goldman Sachs (NYSE: GS)
The first quarter of 2026 has concluded with a historic roar, as global Mergers and Acquisitions (M&A) reached a staggering $438 billion in deal value. This surge, a 155% increase over the same period in 2025, signals a definitive return of "animal spirits" to corporate boardrooms. Despite a backdrop
The global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers and acquisitions. Total deal volume for the quarter reached a staggering $1.25 trillion, marking a 26% increase over
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings.
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
In a move that cements the "human performance" category as a pillar of the future economy, Whoop has officially closed a massive $575 million Series G funding round, catapulting the wearable technology leader to a $10.1 billion valuation. The round was led by the global alternative asset manager TPG
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ system. The clearance marks the final
As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (NYSE: BDX). Known colloquially as BD, the firm has spent the last two years shedding its skin, moving from a broad-based healthcare conglomerate to a high-growth, high-margin "pure-play" medical [...]
As of April 3, 2026, Medtronic plc (NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the Dublin-based medical technology giant is currently navigating the final stages of a profound structural transformation. With the recent partial IPO of its diabetes [...]
